Background The use of assays detecting cytomegalovirus (CMV)–specific T cell–mediated
immunity may individualize the duration of antiviral prophylaxis after transplantation …

Cytomegalovirus is a significant cause of morbidity and mortality in transplantation.
Controversy exists concerning whether prophylactic or pre‐emptive therapy is the optimal …

Background. The role of valganciclovir in the prevention of cytomegalovirus (CMV) disease
in high-risk seropositive transplant patients is not known. Methods. We prospectively …

The natural history of cytomegalovirus (CMV) disease associated with solid organ
transplantation has been modified as a result of the widespread use of antiviral prophylaxis …

Background. Cytomegalovirus (CMV) prevention can be achieved by prophylaxis or
preemptive therapy. We performed a prospective randomized trial to determine whether …

BACKGROUND: Cytomegalovirus (CMV) infections are among the most common infections
following liver transplantation. The main preventive methods for CMV infections are …

The clinical patterns and predictors of cytomegalovirus (CMV) disease in kidney and/or
pancreas transplant patients on ganciclovir (1.0 g po tid) or valganciclovir (450 mg po qd) …

Background Few studies have directly compared preemptive therapy (PET) and antiviral
prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in CMV seropositive (R+) …

Despite remarkable advances in the diagnostic and therapeutic modalities for its
management, cytomegalovirus (CMV) remains one of the most important pathogens …

Cytomegalovirus (CMV) is a common viral pathogen that influences the outcome of liver
transplantation. In addition to the direct effects of CMV syndrome and tissue-invasive …